Protox Therapeutics uses genetic engineering to transform naturally occurring proteins into novel targeted therapeutics for the treatment of prostate diseases and various cancers. Protox is advancing a pipeline of clinical-stage product candidates derived from its PORxin™ and INxin™ technology platforms. Protox’s lead drugs currently in clinical development include PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) and localized prostate cancer, as well as PRX321 for primary brain cancer (glioblastoma multiforme and astrocytoma).

What's New

February 25, 2010
Protox Revises Terms Of Private Placement

February 24, 2010
Protox To Present At The Third International Symposium On Focal Therapy And Imaging Of Prostate And Kidney Cancer

February 4, 2010
Protox Announces Private Placement

January 11, 2010
Protox Announces Positive Phase 2B BPH Results

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

Stock Quote

	LAST TRADE:	$0.48
	TRADE TIME:	3:55PM EST
	CHANGE:	$0.04 (9.09%)
	PREV CLOSE:	$0.44
	OPEN:	$0.45
	BID:	$0.46
	ASK:	$0.48